Sales of pharmaceuticals through retail pharmacies in the nine leading world markets totaled $99.76 billion in the first ten months of 1994, an increase of 5% over the like, year-earlier period, according to new figures published by IMS International.
US retail drug turnover during the January- October period showed an increase of 8% to $40.46 billion, with Canadian sales rising 2% to $2.82 billion, to give an overall North American total for the period of $43.28 billion, up 8% on the same period of 1993, says the study.
Italian sales hit by Govt Reforms The leading seven European markets together experienced growth of 3% during the 10-month period, producing a combined total sales figure of $38.42 billion. The biggest advance among the leading European seven was reported for the UK, with turnover increasing 8% to $4.55 billion, and this was followed by Germany and the Netherlands, which both advanced 6% to reach $11.15 billion and $1.42 billion respectively. Sales in Spain increased 5% to total $3.29 billion, while the French and Belgian markets were up 4% each, to $11.15 billion and $1.33 billion respectively. In Italy the retail pharmacy market plummeted 6% during the period, to a value of $6.13 billion, following the government health reform measures which took effect at the beginning of 1994, according to IMS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze